HhAntag691

06/01/2021 - "Since the introduction of Vismodegib as treatment of recurrent locally advanced basal cell carcinoma (laBCC), clinicians are faced with new dilemmas: 'Can Vismodegib replace complex reconstructions?', 'What is the role of neoadjuvant use of Vismodegib?' and 'What is the best approach in case of complete clinical remission after Vismodegib in a neoadjuvant setting?' Case report and literature review. "
12/01/2019 - "Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients."
01/01/2021 - "Metastatic basal cell carcinoma: complete remission under vismodegib."
09/01/2020 - "Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib."
02/15/2018 - "We report a case and provide complete histological evidence of a 69-year-old gentleman who presented with a recurrent, infiltrative, and sclerosing (morpheiform) basal cell carcinoma on his left upper lip that was entirely eradicated with a three-month course of vismodegib 150 mg daily. "

09/28/2023 - "We show that intraventricular Vismodegib treatment of Math1-cre::Ptch1 Fl/Fl mice leads to complete or partial tumor remission only two days after completed treatment. "
12/01/2022 - "While controversy regarding management recommendations still exists, we present a case of advanced BCC with cranial involvement in an immunocompromised patient where the use of neoadjuvant vismodegib led to a favorable outcome and, surprisingly, complete the pathologic clearance of the tumor."
01/01/2017 - "Although vismodegib exhibits promising therapeutic efficacy in tumor treatment, concerns have been raised from its nonlinear pharmacokinetic (PK) profiles at high doses partly due to low aqueous solubility. "
03/01/2017 - "Vismodegib was effective in clinically clearing the tumor, and the patient has shown no signs of recurrence. "
12/08/2021 - "Based on the data, we investigated the in vivo anti-cancer efficacy of vismodegib in CCC employing a murine model of CCC developed by hydrodynamic tail vein injection method. "

09/28/2023 - "Intraventricular Vismodegib application might provide a promising novel treatment strategy for pediatric medulloblastoma patients. "
08/20/2015 - "Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH) pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent medulloblastoma (MB). "
01/01/2021 - "We report a nanoparticle formulation of the SHH-pathway inhibitor vismodegib that improves efficacy for medulloblastoma, while reducing toxicity. "
01/01/2020 - "Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma."
04/01/2020 - "Phase II trials evaluating vismodegib for SHH medulloblastoma in children and adults have been disappointing. "

09/15/2014 - "Clinical trials with the SMO inhibitor, vismodegib, showed remarkable efficacy in patients with NBCCS, which finally led to its FDA approval in 2012."
01/01/2022 - "Long-term efficacy of a Vismodegib regime including a 1-week drug holiday every month in two patients with Gorlin Goltz syndrome."
01/01/2021 - "This study evaluates the effectiveness of vismodegib for the treatment of laBCC, mBCC and basal cell nevus syndrome (BCNS) patients, and the tumour characteristics associated with a higher probability of achieving a complete response in the Netherlands. "
07/01/2018 - "The full European approval of vismodegib was based on the results of two phase II, open-label, noncomparative, international trials (ERIVANCE BCC and STEVIE), both of which showed high rates of tumour control in the indicated patient populations, including individuals with or without Gorlin syndrome. "
10/01/2023 - "GDC-0449 could be used to treat OKCs, especially NBCCS-related OKCs with PTCH1 truncated mutations. "

01/21/2022 - "Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies."
04/13/2022 - "A total of 53 patients with locally advanced BCC who initiated treatment with vismodegib between 2016 and 2018 were included in the study, which was embedded in the German ADOReg skin cancer registry. "
01/21/2022 - "Vismodegib (VSD) is a hedgehog blocker approved for the prevention and treatment of skin cancer. "
01/03/2020 - "Vismodegib (VMD) is a hedgehog inhibitor which indicated for basal cell skin cancer (BCC). "
06/30/2019 - "Nanoformulation for potential topical delivery of Vismodegib in skin cancer treatment."